| Literature DB >> 28700019 |
Yu Kang1, Wei Wang1, Hang Zhao1, Zhiqing Qiao1, Xuedong Shen1, Ben He1.
Abstract
BACKGROUNDS:: Despite their clear therapeutic benefits, anthracycline-induced cardiotoxicity is a major concern limiting the ability to reduce morbidity and mortality associated with cancers. The early identification of anthracycline-induced cardiotoxicity is of vital importance to assess the cardiac risk against the potential cancer treatment.Entities:
Year: 2017 PMID: 28700019 PMCID: PMC5576117 DOI: 10.5935/abc.20170097
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
LVEF and speckle-tracking indices in doxorubicin-treated and control rats
| Control group | Group 1 | Group 2 | Group 3 | Group 4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | After | P value | Baseline | After | P value | Baseline | After | P value | Baseline | After | P value | Baseline | After | P value | |
| LVEF (%) | 85.4 ± 0.9 | 84.8 ± 2.9 | 0.591 | 86.2 ± 1.9 | 86.4 ± 2.3 | 0.890 | 84.6 ± 3.3 | 84.3 ± 2.9 | 0.714 | 83.9 ± 2.4 | 83.3 ± 2.3 | 0.220 | 85.5 ± 1.2 | 82.5 ± 1.8 | 0.006 |
| Srad (%) | 52.2 ± 3.6 | 52.6 ± 3.1 | 0.730 | 51.2 ± 6.8 | 49.4 ± 5.2 | 0.061 | 52.1 ± 5.6 | 43.2 ± 5.7 | 0.000 | 52.5 ± 5.1 | 38.6 ± 4.8 | 0.000 | 52.3 ± 7.3 | 34.6 ± 7.4 | 0.000 |
| Scirc (%) | –17.2 ± 3.1 | –18.2 ± 4.6 | 0.551 | –16.1 ± 2.0 | –17.0 ± 2.2 | 0.113 | –17.2 ± 2.4 | –16.7 ± 2.4 | 0.578 | –17.0 ± 2.7 | –17.9 ± 2.0 | 0.634 | –17.4 ± 2.1 | –14.1 ± 1.8 | 0.004 |
| SRrad (sec-1) | 5.7 ± 1.1 | 5.5 ± 1.2 | 0.821 | 5.9 ± 0.8 | 6.1 ± 1.2 | 0.617 | 6.0 ± 0.9 | 6.0 ± 1.1 | 0.983 | 5.6 ± 1.1 | 5.6 ± 1.1 | 0.987 | 5.6 ± 1.0 | 5.5 ± 1.1 | 0.786 |
| SRcirc (sec-1) | 4.5 ± 0.7 | 4.9 ± 0.5 | 0.137 | 4.5 ± 1.2 | 4.7 ± 0.9 | 0.556 | 4.3 ± 1.0 | 4.3 ± 0.8 | 0.571 | 4.6 ± 0.9 | 4.3 ± 0.5 | 0.409 | 4.7 ± 0.7 | 4.5 ± 0.7 | 0.179 |
LVEF: left ventricular ejection fraction; Scirc: circumferential strain; Srad: radial strain; SRcirc: circumferential strain rate; SRrad: radial strain rate.
p < 0.05 compared with that of baseline.
Figure 1Radial strain curves obtained at the short-axis view of rats after doxorubicin treatment. A: rat from group 1, radial strain = 55.23%; B: rat from group 2, radial strain = 41.63%; C: rat from group 3, radial strain = 29.71%; D: rat from group 4, radial strain = 24.95%.
Cardiomyopathy scores in Wistar rats treated with doxorubicin for 4 weeks
| Dose of doxorubicin (mg/kg/w) | No. of animals | Cardiomyopathy score | |||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 1.5 | 2 | 2.5 | 3 | ||
| 4 | 8 | 0 | 2 | 3 | 3 | 0 | 0 |
| 3.5 | 7 | 2 | 2 | 2 | 1 | 0 | 0 |
| 3 | 8 | 4 | 2 | 2 | 0 | 0 | 0 |
| 2.5 | 8 | 6 | 2 | 0 | 0 | 0 | 0 |
| Saline control | 5 | 5 | 0 | 0 | 0 | 0 | 0 |
Cardiomyopathy scores are based on the percentage of myocytes showing cytoplasmic vacuolization and/or myofibrillar loss and are graded from 0 to 3 as follows: 0 = no alterations, 1 ≤ 5%, 1.5 = 5% to 15%, 2.0 = 16% to 25%, 2.5 = 26% to 35%, and 3 ≥ 35%.
Cardiomyopathy scores were significantly (p < 0.05) higher than in those receiving 3 mg/kg/w or less doxorubicin.
Cardiomyopathy scores were significantly (p < 0.05) higher than in those receiving 2.5 mg/kg/w or less doxorubicin.
Figure 2Myocardial changes after doxorubicin treatment at the light microscopy level (× 400). Vacuolization of the cytoplasm, loss of myofbrils was more severe in rats from group 4 (D). A: rat from group 1; B: rat from group 2; C: rat from group 3; D: rat from group 4.
Figure 3Scatter diagram of serum levels of cTnI in individual rat. *: p < 0.05 compared with that of baseline.
Figure 4Correlations between radial strains and cTnI levels.
Figure 5Correlations between radial strains and cardiomyopathy scores.